Work

Abstract 2103: Pharmacogenomic biomarkers of oncology drugs approved by the US FDA classified on the basis of BEST (Biomarkers, EndpointS, and other Tools) resource: systematic review

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-2103

Authors: Tariq H. Alqurayshah, SFDA Oncology and Hematology Group

Institution: Saudi Food and Drug Authority

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409625464

Cites:

Cited by:

Related to: 10